Zosano Pharma (ZSAN) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Zosano Pharma (ZSAN) Reported 3Q EPS Miss; Roth Capital Reiterates Buy
November 11, 2015 7:56 AM ESTRoth Capital reiterated a Buy rating on Zosano Pharma (NASDAQ: ZSAN), and cut the price target to $7.00 (from $11.00), following the company's 3Q earnings report. ZSAN reported a EPS loss of ($0.72) versus consensus of ($0.61).
Analyst Scott Henry commented, "ZSAN reported a 3Q15 EPS loss... More
